<DOC>
	<DOC>NCT01760460</DOC>
	<brief_summary>This study will evaluate the effects of anacetrapib (MK-0859) on low-density lipoprotein-cholesterol (LDL-C) when compared to placebo in Japanese participants with dyslipidemia when added to an existing statin-modifying therapy.</brief_summary>
	<brief_title>A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Anacetrapib</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>If female, cannot be of reproductive potential Treatment with an appropriate, stable dose of statin Â± other lipid modifying therapy for at least 6 weeks and who is not at LDLC goal per their category in the Japan Atherosclerosis Society guidelines Previously participated in a study with a cholesteryl ester transfer protein (CETP) inhibitor Homozygous and heterozygous familial hypercholesterolemia Severe chronic heart failure Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), unstable angina, or stroke within 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>